Nicolas Cruz Dardiz, MD
Endocrinology, Diabetes & Metabolism · Hatillo, PRNPI 1619351103
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,904 and has fallen 71.1% since, to $551 in 2025.
Across 209 payments — averaging $29.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$885
- Amgen$743
- Medtronic$644
- Novo Nordisk$613
- Sanofi-aventis U.S. LLC$436
- plus $2K from 12 others
What the payments were for
- Travel & lodging$190%
- Food & beverage$6,224100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,209 |
| Boehringer Ingelheim | 29 | $885 |
| Amgen | 14 | $743 |
| Medtronic(2 entities) | 9 | $644 |
| Novo Nordisk | 29 | $613 |
| Sanofi-aventis U.S. LLC | 25 | $436 |
| Eli Lilly Export S.A. Puerto Rico Branch | 19 | $411 |
| Johnson & Johnson | 8 | $253 |
| Merck | 11 | $195 |
| Lilly USA, LLC | 2 | $143 |
| E.r. Squibb & Sons, L.L.C. | 1 | $131 |
| PBG Puerto Rico LLC | 7 | $129 |
| Bayer | 1 | $125 |
| Madrigal Pharmaceuticals | 1 | $118 |
| Abbott | 5 | $89 |
| Bayer Puerto Rico Inc. | 2 | $50 |
| Dexcom, Inc. | 2 | $37 |
| Radius Health, Inc. | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,243 in reported general payments places this provider in the 60th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 141 | $91,653 |
| OzempicSemaglutide | 81 | $79,591 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 102 | $64,538 |
| Jentadueto XrLinagliptin/Metformin Hcl | 89 | $48,785 |
| MounjaroTirzepatide | 36 | $41,902 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $40,021 |
| GlyxambiEmpagliflozin/Linagliptin | 42 | $30,305 |
| SynthroidLevothyroxine Sodium | 356 | $21,157 |
| JardianceEmpagliflozin | 26 | $19,411 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $16,529 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $15,001 |
| TrulicityDulaglutide | 13 | $12,796 |
| TradjentaLinagliptin | 20 | $11,629 |
| LantusInsulin Glargine,hum.Rec.Anlog | 120 | $10,279 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $3,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Synjardy Xr, Jentadueto Xr, Glyxambi, Jardiance | $885 | $266,323420 claims |
| Novo NordiskOzempic | $613 | $79,59181 claims |
| Lilly USA, LLCMounjaro, Trulicity | $143 | $54,69849 claims |
| MerckJanumet Xr | $195 | $15,00126 claims |
| Sanofi-aventis U.S. LLCLantus | $436 | $10,279120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Hatillo
- Luis Hernandez VazquezHatillo$20K
- Gabriel Mora OsoriaHatillo$9K
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Milliette Alvarado SantiagoRio Piedras$75K
- Altagracia Alcantara GonzalezBayamon$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.